Straits Times Index
3,169.76 -17.90 (-0.56%) Nikkei
37,063.56 -1,016.14 (-2.67%) Hang Seng
16,200.41 -185.46 (-1.13%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
62,160.14 +529.79 (+0.86%) CMC Crypto 200
1,290.17 +404.64 (+44.62%)
Harrow, Inc. (HROW)
After hours:
| Previous close | 11.82 |
| Open | 11.75 |
| Bid | 10.82 x 200 |
| Ask | 10.91 x 100 |
| Day's range | 10.83 - 11.87 |
| 52-week range | 7.60 - 28.25 |
| Volume | |
| Avg. volume | 437,877 |
| Market cap | 383.684M |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.65 |
Business WireMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
NASHVILLE, Tenn., April 02, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019. The capital raised will primarily support the further development
Insider MonkeyHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript March 20, 2024 Harrow Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Harrow’s Fourth Quarter and Year-End 2023 Earnings Conference Call. My name is […]
GuruFocus.comHarrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023
Adjusted EBITDA Soars as Harrow Inc (HROW) Navigates Market Challenges
